Issue 139 • February 2024
Inside the world of priority review vouchers where time is money
FDA priority review vouchers were designed to incentivise innovation for low-commercial value-diseases, but some challenges remain
The Big Interview
Tackling the rise of fake anti-obesity drugs on the market
In Data
Leading innovators in aircraft air conditioning
Thematic Take
Internet of Things in pharma
In association with
